The Therapeutic Impact of New Migraine Discoveries

Murray, C.J.; Vos, T.; Lozano, R.; Naghavi, M.; Flaxman, A.D.; Michaud, C.; Ezzati, M.; Shibuya, K.; Salomon, J.A.; Abdalla, S.; Aboyans, V.; Abraham, J.; Ackerman, I.; Aggarwal, R.; Ahn, S.Y.; Ali, M.K.; Alvarado, M.; Anderson, H.R.; Anderson, L.M.; Andrews, K.G.; Atkinson, C.; Baddour, L.M.; Bahalim, A.N.; Barker-Collo, S.; Barrero, L.H.; Bartels, D.H.; Basáñez, M.G.; Baxter, A.; Bell, M.L.; Benjamin, E.J.; Bennett, D.; Bernabé, E.; Bhalla, K.; Bhandari, B.; Bikbov, B.; Bin Abdulhak, A.; Birbeck, G.; Black, J.A.; Blencowe, H.; Blore, J.D.; Blyth, F.; Bolliger, I.; Bonaventure, A.; Boufous, S.; Bourne, R.; Boussinesq, M.; Braithwaite, T.; Brayne, C.; Bridgett, L.; Brooker, S.; Brooks, P.; Brugha, T.S.; Bryan-Hancock, C.; Bucello, C.; Buchbinder, R.; Buckle, G.; Budke, C.M.; Burch, M.; Burney, P.; Burstein, R.; Calabria, B.; Campbell, B.; Canter, C.E.; Carabin, H.; Carapetis, J.; Carmona, L.; Cella, C.; Charlson, F.; Chen, H.; Cheng, A.T.; Chou, D.; Chugh, S.S.; Coffeng, L.E.; Colan, S.D.; Colquhoun, S.; Colson, K.E.; Condon, J.; Connor, M.D.; Cooper, L.T.; Corriere, M.; Cortinovis, M.; de Vaccaro, K.C.; Couser, W.; Cowie, B.C.; Criqui, M.H.; Cross, M.; Dabhadkar, K.C.; Dahiya, M.; Dahodwala, N.; Damsere-Derry, J.; Danaei, G.; Davis, A.; De Leo, D.; Degenhardt, L.; Dellavalle, R.; Delossantos, A.; Denenberg, J.; Derrett, S.; Des Jarlais, D.C.; Dharmaratne, S.D.; Dherani, M.; Diaz-Torne, C.; Dolk, H.; Dorsey, E.R.; Driscoll, T.; Duber, H.; Ebel, B.; Edmond, K.; Elbaz, A.; Ali, S.E.; Erskine, H.; Erwin, P.J.; Espindola, P.; Ewoigbokhan, S.E.; Farzadfar, F.; Feigin, V.; Felson, D.T.; Ferrari, A.; Ferri, C.P.; Fèvre, E.M.; Finucane, M.M.; Flaxman, S.; Flood, L.; Foreman, K.; Forouzanfar, M.H.; Fowkes, F.G.; Fransen, M.; Freeman, M.K.; Gabbe, B.J.; Gabriel, S.E.; Gakidou, E.; Ganatra, H.A.; Garcia, B.; Gaspari, F.; Gillum, R.F.; Gmel, G.; Gonzalez-Medina, D.; Gosselin, R.; Grainger, R.; Grant, B.; Groeger, J.; Guillemin, F.; Gunnell, D.; Gupta, R.; Haagsma, J.; Hagan, H.; Halasa, Y.A.; Hall, W.; Haring, D.; Haro, J.M.; Harrison, J.E.; Havmoeller, R.; Hay, R.J.; Higashi, H.; Hill, C.; Hoen, B.; Hoffman, H.; Hotez, P.J.; Hoy, D.; Huang, J.J.; Ibeanusi, S.E.; Jacobsen, K.H.; James, S.L.; Jarvis, D.; Jasrasaria, R.; Jayaraman, S.; Johns, N.; Jonas, J.B.; Karthikeyan, G.; Kassebaum, N.; Kawakami, N.; Keren, A.; Khoo, J.P.; King, C.H.; Knowlton, L.M.; Kobusingye, O.; Koranteng, A.; Krishnamurthi, R.; Laden, F.; Lalloo, R.; Laslett, L.L.; Lathlean, T.; Leasher, J.L.; Lee, Y.Y.; Leigh, J.; Levinson, D.; Lim, S.S.; Limb, E.; Lin, J.K.; Lipnick, M.; Lipshultz, S.E.; Liu, W.; Loane, M.; Ohno, S.L.; Lyons, R.; Mabweijano, J.; MacIntyre, M.F.; Malekzadeh, R.; Mallinger, L.; Manivannan, S.; Marcenes, W.; March, L.; Margolis, D.J.; Marks, G.B.; Marks, R.; Matsumori, A.; Matzopoulos, R.; Mayosi, B.M.; McAnulty, J.H.; McDermott, M.M.; McGill, N.; McGrath, J.; Medina-Mora, M.E.; Meltzer, M.; Mensah, G.A.; Merriman, T.R.; Meyer, A.C.; Miglioli, V.; Miller, M.; Miller, T.R.; Mitchell, P.B.; Mock, C.; Mocumbi, A.O.; Moffitt, T.E.; Mokdad, A.A.; Monasta, L.; Montico, M.; Moradi-Lakeh, M.; Moran, A.; Morawska, L.; Mori, R.; Murdoch, M.E.; Mwaniki, M.K.; Naidoo, K.; Nair, M.N.; Naldi, L.; Narayan, K.M.; Nelson, P.K.; Nelson, R.G.; Nevitt, M.C.; Newton, C.R.; Nolte, S.; Norman, P.; Norman, R.; O’Donnell, M.; O’Hanlon, S.; Olives, C.; Omer, S.B.; Ortblad, K.; Osborne, R.; Ozgediz, D.; Page, A.; Pahari, B.; Pandian, J.D.; Rivero, A.P.; Patten, S.B.; Pearce, N.; Padilla, R.P.; Perez-Ruiz, F.; Perico, N.; Pesudovs, K.; Phillips, D.; Phillips, M.R.; Pierce, K.; Pion, S.; Polanczyk, G.V.; Polinder, S.; Pope, C.A., III; Popova, S.; Porrini, E.; Pourmalek, F.; Prince, M.; Pullan, R.L.; Ramaiah, K.D.; Ranganathan, D.; Razavi, H.; Regan, M.; Rehm, J.T.; Rein, D.B.; Remuzzi, G.; Richardson, K.; Rivara, F.P.; Roberts, T.; Robinson, C.; De Leòn, F.R.; Ronfani, L.; Room, R.; Rosenfeld, L.C.; Rushton, L.; Sacco, R.L.; Saha, S.; Sampson, U.; Sanchez-Riera, L.; Sanman, E.; Schwebel, D.C.; Scott, J.G.; Segui-Gomez, M.; Shahraz, S.; Shepard, D.S.; Shin, H.; Shivakoti, R.; Singh, D.; Singh, G.M.; Singh, J.A.; Singleton, J.; Sleet, D.A.; Sliwa, K.; Smith, E.; Smith, J.L.; Stapelberg, N.J.; Steer, A.; Steiner, T.; Stolk, W.A.; Stovner, L.J.; Sudfeld, C.; Syed, S.; Tamburlini, G.; Tavakkoli, M.; Taylor, H.R.; Taylor, J.A.; Taylor, W.J.; Thomas, B.; Thomson, W.M.; Thurston, G.D.; Tleyjeh, I.M.; Tonelli, M.; Towbin, J.A.; Truelsen, T.; Tsilimbaris, M.K.; Ubeda, C.; Undurraga, E.A.; van der Werf, M.J.; van Os, J.; Vavilala, M.S.; Venketasubramanian, N.; Wang, M.; Wang, W.; Watt, K.; Weatherall, D.J.; Weinstock, M.A.; Weintraub, R.; Weisskopf, M.G.; Weissman, M.M.; White, R.A.; Whiteford, H.; Wiebe, N.; Wiersma, S.T.; Wilkinson, J.D.; Williams, H.C.; Williams, S.R.; Witt, E.; Wolfe, F.; Woolf, A.D.; Wulf, S.; Yeh, P.H.; Zaidi, A.K.; Zheng, Z.J.; Zonies, D.; Lopez, A.D.; AlMazroa, M.A.; Memish, Z.A. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859), 2197-2223.
[http://dx.doi.org/10.1016/S0140-6736(12)61689-4] [PMID: 23245608]

Maniyar, F.H.; Sprenger, T.; Monteith, T.; Schankin, C.; Goadsby, P.J. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain, 2014, 137(Pt 1), 232-241.
[http://dx.doi.org/10.1093/brain/awt320] [PMID: 24277718]

K.S.L. Patterns of cerebral integration indicated by the scotomas of migraine. Arch. Neurol. Psychiatry, 1941, 46, 331-339.
[http://dx.doi.org/10.1001/archneurpsyc.1941.02280200137007]

Silberstein, S.D. Considerations for management of migraine symptoms in the primary care setting. Postgrad. Med., 2016, 128(5), 523-537.
[http://dx.doi.org/10.1080/00325481.2016.1175912] [PMID: 27078039]

Viana, M.; Linde, M.; Sances, G.; Ghiotto, N.; Guaschino, E.; Allena, M.; Terrazzino, S.; Nappi, G.; Goadsby, P.J.; Tassorelli, C. Migraine aura symptoms: Duration, succession and temporal relationship to headache. Cephalalgia, 2016, 36(5), 413-421.
[http://dx.doi.org/10.1177/0333102415593089] [PMID: 26156076]

Russell, M.B.; Ducros, A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol., 2011, 10(5), 457-470.
[http://dx.doi.org/10.1016/S1474-4422(11)70048-5] [PMID: 21458376]

Headache Classification Committee of the International Headache, S., The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 2013, 33(9), 629-808.
[http://dx.doi.org/10.1177/0333102413485658] [PMID: 23771276]

Blau, J.N. Migraine postdromes: symptoms after attacks. Cephalalgia, 1991, 11(5), 229-231.
[http://dx.doi.org/10.1046/j.1468-2982.1991.1105229.x] [PMID: 1773437]

Giffin, N.J.; Lipton, R.B.; Silberstein, S.D.; Olesen, J.; Goadsby, P.J. The migraine postdrome: An electronic diary study. Neurology, 2016, 87(3), 309-313.
[http://dx.doi.org/10.1212/WNL.0000000000002789] [PMID: 27335112]

Edvinsson, L. Tracing neural connections to pain pathways with relevance to primary headaches. Cephalalgia, 2011, 31(6), 737-747.
[http://dx.doi.org/10.1177/0333102411398152] [PMID: 21335366]

Liu, Y.; Broman, J.; Zhang, M.; Edvinsson, L. Brainstem and thalamic projections from a craniovascular sensory nervous centre in the rostral cervical spinal dorsal horn of rats. Cephalalgia, 2009, 29(9), 935-948.
[http://dx.doi.org/10.1111/j.1468-2982.2008.01829.x] [PMID: 19250290]

Mokha, S.S.; McMillan, J.A.; Iggo, A. Pathways mediating descending control of spinal nociceptive transmission from the nuclei locus coeruleus (LC) and raphe magnus (NRM) in the cat. Exp. Brain Res., 1986, 61(3), 597-606.
[http://dx.doi.org/10.1007/BF00237586] [PMID: 3007190]

Li, Y.Q.; Takada, M.; Shinonaga, Y.; Mizuno, N. Direct projections from the midbrain periaqueductal gray and the dorsal raphe nucleus to the trigeminal sensory complex in the rat. Neuroscience, 1993, 54(2), 431-443.
[http://dx.doi.org/10.1016/0306-4522(93)90264-G] [PMID: 7687754]

Szabó, N.; Kincses, Z.T.; Párdutz, A.; Tajti, J.; Szok, D.; Tuka, B.; Király, A.; Babos, M.; Vörös, E.; Bomboi, G.; Orzi, F.; Vécsei, L. White matter microstructural alterations in migraine: a diffusion-weighted MRI study. Pain, 2012, 153(3), 651-656.
[http://dx.doi.org/10.1016/j.pain.2011.11.029] [PMID: 22244439]

Amin, F.M.; Asghar, M.S.; Hougaard, A.; Hansen, A.E.; Larsen, V.A.; de Koning, P.J.; Larsson, H.B.; Olesen, J.; Ashina, M. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol., 2013, 12(5), 454-461.
[http://dx.doi.org/10.1016/S1474-4422(13)70067-X] [PMID: 23578775]

Tajti, J.; Szok, D.; Majláth, Z.; Tuka, B.; Csáti, A.; Vécsei, L. Migraine and neuropeptides. Neuropeptides, 2015, 52, 19-30.
[http://dx.doi.org/10.1016/j.npep.2015.03.006] [PMID: 26094101]

Xanthos, D.N.; Sandkühler, J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat. Rev. Neurosci., 2014, 15(1), 43-53.
[http://dx.doi.org/10.1038/nrn3617] [PMID: 24281245]

Chiu, I.M.; von Hehn, C.A.; Woolf, C.J. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat. Neurosci., 2012, 15(8), 1063-1067.
[http://dx.doi.org/10.1038/nn.3144] [PMID: 22837035]

Noseda, R.; Burstein, R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain, 2013, 154(Suppl. 1), S44-S53.
[http://dx.doi.org/10.1016/j.pain.2013.07.021] [PMID: 23891892]

Zhang, X.; Levy, D.; Noseda, R.; Kainz, V.; Jakubowski, M.; Burstein, R. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J. Neurosci., 2010, 30(26), 8807-8814.
[http://dx.doi.org/10.1523/JNEUROSCI.0511-10.2010] [PMID: 20592202]

Ferrari, M.D.; Goadsby, P.J.; Roon, K.I.; Lipton, R.B. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia, 2002, 22(8), 633-658.
[http://dx.doi.org/10.1046/j.1468-2982.2002.00404.x] [PMID: 12383060]

Diener, H.C. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia, 1999, 19(6), 581-588.
[http://dx.doi.org/10.1046/j.1468-2982.1999.019006581.x] [PMID: 10448545]

Derry, C.J.; Derry, S.; Moore, R.A. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst. Rev., 2014, (5)CD009108
[http://dx.doi.org/10.1002/14651858.CD009108.pub2] [PMID: 24865446]

Limmroth, V.; Kazarawa, Z.; Fritsche, G.; Diener, H.C. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet, 1999, 353(9150), 378.
[http://dx.doi.org/10.1016/S0140-6736(05)74950-3] [PMID: 9950449]

Tajti, J.; Majláth, Z.; Szok, D.; Csáti, A.; Vécsei, L. Drug safety in acute migraine treatment. Expert Opin. Drug Saf., 2015, 14(6), 891-909.
[http://dx.doi.org/10.1517/14740338.2015.1026325] [PMID: 25773005]

O’Quinn, S.; Davis, R.L.; Gutterman, D.L.; Pait, G.D.; Fox, A.W. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia, 1999, 19(4), 223-231.
[http://dx.doi.org/10.1046/j.1468-2982.1999.019004223.x] [PMID: 10376167]

Welch, K.M.; Mathew, N.T.; Stone, P.; Rosamond, W.; Saiers, J.; Gutterman, D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia, 2000, 20(8), 687-695.
[http://dx.doi.org/10.1046/j.1468-2982.2000.00116.x] [PMID: 11167896]

Schaefer, S.M.; Gottschalk, C.H.; Jabbari, B. Treatment of chronic migraine with focus on botulinum neurotoxins. Toxins (Basel), 2015, 7(7), 2615-2628.
[http://dx.doi.org/10.3390/toxins7072615] [PMID: 26184313]

Szok, D.; Csáti, A.; Vécsei, L.; Tajti, J. Treatment of chronic migraine with Onabotulinumtoxin A: Mode of action, efficacy and safety. Toxins (Basel), 2015, 7(7), 2659-2673.
[http://dx.doi.org/10.3390/toxins7072659] [PMID: 26193319]

Tajti, J.; Szok, D.; Tuka, B.; Csáti, A.; Kuris, A.; Majláth, Z.; Lukács, M.; Vécsei, L. [Botulinum neurotoxin--a therapy in migraine Ideggyogy. Sz., 2012, 65(3-4), 77-82.
[PMID: 23136725]

Edvinsson, L.; Villalón, C.M. MaassenVanDenBrink, A. Basic mechanisms of migraine and its acute treatment. Pharmacol. Ther., 2012, 136(3), 319-333.
[http://dx.doi.org/10.1016/j.pharmthera.2012.08.011] [PMID: 22939884]

Curran, D.A.; Hinterberger, H.; Lance, J.W. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain, 1965, 88(5), 997-1010.
[http://dx.doi.org/10.1093/brain/88.5.997] [PMID: 5325360]

Feniuk, W.; Humphrey, P.P.; Perren, M.J. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br. J. Pharmacol., 1989, 96(1), 83-90.
[http://dx.doi.org/10.1111/j.1476-5381.1989.tb11787.x] [PMID: 2538184]

Cohen, M.L.; Johnson, K.W.; Schenck, K.W.; Phebus, L.A. Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. Cephalalgia, 1997, 17(6), 631-638.
[http://dx.doi.org/10.1046/j.1468-2982.1997.1706631.x] [PMID: 9350382]

Nilsson, T.; Longmore, J.; Shaw, D.; Olesen, I.J.; Edvinsson, L. Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br. J. Pharmacol., 1999, 128(6), 1133-1140.
[http://dx.doi.org/10.1038/sj.bjp.0702773] [PMID: 10578124]

Edvinsson, L.; Uddman, E.; Wackenfors, A.; Davenport, A.; Longmore, J.; Malmsjö, M. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clin. Sci. (Lond.), 2005, 109(3), 335-342.
[http://dx.doi.org/10.1042/CS20050016] [PMID: 15853772]

Williamson, D.J.; Hargreaves, R.J.; Hill, R.G.; Shepheard, S.L. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies. Cephalalgia, 1997, 17(4), 525-531.
[http://dx.doi.org/10.1046/j.1468-2982.1997.1704525.x] [PMID: 9209774]

Williamson, D.J.; Shepheard, S.L.; Hill, R.G.; Hargreaves, R.J. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol., 1997, 328(1), 61-64.
[http://dx.doi.org/10.1016/S0014-2999(97)83028-2] [PMID: 9203569]

Hoskin, K.L.; Kaube, H.; Goadsby, P.J. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain, 1996, 119(Pt 5), 1419-1428.
[http://dx.doi.org/10.1093/brain/119.5.1419] [PMID: 8931567]

Hoyer, D.; Clarke, D.E.; Fozard, J.R.; Hartig, P.R.; Martin, G.R.; Mylecharane, E.J.; Saxena, P.R.; Humphrey, P.P. International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 1994, 46(2), 157-203.
[PMID: 7938165]

Lee, D.K.; George, S.R.; Evans, J.F.; Lynch, K.R.; O’Dowd, B.F. Orphan G protein-coupled receptors in the CNS. Curr. Opin. Pharmacol., 2001, 1(1), 31-39.
[http://dx.doi.org/10.1016/S1471-4892(01)00003-0] [PMID: 11712532]

Waeber, C.; Moskowitz, M.A. [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch. Pharmacol., 1995, 352(3), 263-275.
[http://dx.doi.org/10.1007/BF00168556] [PMID: 8584041]

Tfelt-Hansen, P.; Saxena, P.R.; Dahlöf, C.; Pascual, J.; Láinez, M.; Henry, P.; Diener, H.; Schoenen, J.; Ferrari, M.D.; Goadsby, P.J. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain, 2000, 123(Pt 1), 9-18.
[http://dx.doi.org/10.1093/brain/123.1.9] [PMID: 10611116]

Hoyer, D.; Hannon, J.P.; Martin, G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav., 2002, 71(4), 533-554.
[http://dx.doi.org/10.1016/S0091-3057(01)00746-8] [PMID: 11888546]

Amrutkar, D.V.; Ploug, K.B.; Hay-Schmidt, A.; Porreca, F.; Olesen, J.; Jansen-Olesen, I. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain, 2012, 153(4), 830-838.
[http://dx.doi.org/10.1016/j.pain.2012.01.005] [PMID: 22305629]

Classey, J.D.; Bartsch, T.; Goadsby, P.J. Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. Brain Res., 2010, 1361, 76-85.
[http://dx.doi.org/10.1016/j.brainres.2010.09.004] [PMID: 20833155]

Cohen, Z.; Bouchelet, I.; Olivier, A.; Villemure, J.G.; Ball, R.; Stanimirovic, D.B.; Hamel, E. Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J. Cereb. Blood Flow Metab., 1999, 19(8), 908-917.
[http://dx.doi.org/10.1097/00004647-199908000-00010] [PMID: 10458598]

Tajti, J.; Csáti, A.; Vécsei, L. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. Expert Opin. Drug Metab. Toxicol., 2014, 10(11), 1509-1520.
[http://dx.doi.org/10.1517/17425255.2014.963554] [PMID: 25253587]

Johnson, K.W.; Schaus, J.M.; Durkin, M.M.; Audia, J.E.; Kaldor, S.W.; Flaugh, M.E.; Adham, N.; Zgombick, J.M.; Cohen, M.L.; Branchek, T.A.; Phebus, L.A. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport, 1997, 8(9-10), 2237-2240.
[http://dx.doi.org/10.1097/00001756-199707070-00029] [PMID: 9243618]

Wainscott, D.B.; Krushinski, J.H., Jr; Audia, J.E.; Schaus, J.M.; Zgombick, J.M.; Lucaites, V.L.; Nelson, D.L. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn Schmiedebergs Arch. Pharmacol., 2005, 371(3), 169-177.
[http://dx.doi.org/10.1007/s00210-005-1035-9] [PMID: 15900510]

Shepheard, S.; Edvinsson, L.; Cumberbatch, M.; Williamson, D.; Mason, G.; Webb, J.; Boyce, S.; Hill, R.; Hargreaves, R. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia, 1999, 19(10), 851-858.
[http://dx.doi.org/10.1046/j.1468-2982.1999.1910851.x] [PMID: 10668103]

Cohen, M.L.; Schenck, K. Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha). Br. J. Pharmacol., 2000, 131(3), 562-568.
[http://dx.doi.org/10.1038/sj.bjp.0703587] [PMID: 11015308]

Goldstein, D.J.; Roon, K.I.; Offen, W.W.; Ramadan, N.M.; Phebus, L.A.; Johnson, K.W.; Schaus, J.M.; Ferrari, M.D. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet, 2001, 358(9289), 1230-1234.
[http://dx.doi.org/10.1016/S0140-6736(01)06347-4] [PMID: 11675061]

Nelson, D.L.; Phebus, L.A.; Johnson, K.W.; Wainscott, D.B.; Cohen, M.L.; Calligaro, D.O.; Xu, Y.C. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia, 2010, 30(10), 1159-1169.
[http://dx.doi.org/10.1177/0333102410370873] [PMID: 20855361]

Capi, M.; de Andrés, F.; Lionetto, L.; Gentile, G.; Cipolla, F.; Negro, A.; Borro, M.; Martelletti, P.; Curto, M. Lasmiditan for the treatment of migraine. Expert Opin. Investig. Drugs, 2017, 26(2), 227-234.
[http://dx.doi.org/10.1080/13543784.2017.1280457] [PMID: 28076702]

Ferrari, M.D.; Färkkilä, M.; Reuter, U.; Pilgrim, A.; Davis, C.; Krauss, M.; Diener, H.C. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial. Cephalalgia, 2010, 30(10), 1170-1178.
[http://dx.doi.org/10.1177/0333102410375512] [PMID: 20855362]

Tfelt-Hansen, P.C.; Olesen, J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J. Headache Pain, 2012, 13(4), 271-275.
[http://dx.doi.org/10.1007/s10194-012-0428-7] [PMID: 22430431]

Reuter, U.; Israel, H.; Neeb, L. The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther. Adv. Neurol. Disorder., 2015, 8(1), 46-54.
[http://dx.doi.org/10.1177/1756285614562419] [PMID: 25584073]

Färkkilä, M.; Diener, H.C.; Géraud, G.; Láinez, M.; Schoenen, J.; Harner, N.; Pilgrim, A.; Reuter, U. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol., 2012, 11(5), 405-413.
[http://dx.doi.org/10.1016/S1474-4422(12)70047-9] [PMID: 22459549]

Bhatt, D.K.; Gupta, S.; Jansen-Olesen, I.; Andrews, J.S.; Olesen, J. NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia, 2013, 33(2), 87-100.
[http://dx.doi.org/10.1177/0333102412466967] [PMID: 23155193]

Vaughan, D.; Speed, J.; Medve, R.; Andrews, J.S. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. Clin. Ther., 2010, 32(1), 146-160.
[http://dx.doi.org/10.1016/j.clinthera.2010.01.006] [PMID: 20171420]

Hougaard, A.; Hauge, A.W.; Guo, S.; Tfelt-Hansen, P. The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: A randomized, double-blind, placebo-controlled cross-over study. Scand. J. Pain, 2013, 4(1), 48-52.
[http://dx.doi.org/10.1016/j.sjpain.2012.08.002] [PMID: 29913885]

Ferrari, A.; Spaccapelo, L.; Pinetti, D.; Tacchi, R.; Bertolini, A. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia, 2009, 29(4), 423-429.
[http://dx.doi.org/10.1111/j.1468-2982.2008.01749.x] [PMID: 19170689]

Vieira, D.S. Naffah-Mazzacoratti, Mda.G.; Zukerman, E.; Senne Soares, C.A.; Cavalheiro, E.A.; Peres, M.F. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache, 2007, 47(6), 842-847.
[http://dx.doi.org/10.1111/j.1526-4610.2007.00812.x] [PMID: 17578532]

Gorji, A.; Scheller, D.; Straub, H.; Tegtmeier, F.; Köhling, R.; Höhling, J.M.; Tuxhorn, I.; Ebner, A.; Wolf, P.; Werner Panneck, H.; Oppel, F.; Speckmann, E.J. Spreading depression in human neocortical slices. Brain Res., 2001, 906(1-2), 74-83.
[http://dx.doi.org/10.1016/S0006-8993(01)02557-4] [PMID: 11430863]

Xiao, Y.; Richter, J.A.; Hurley, J.H. Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Mol. Pain, 2008, 4, 12.
[http://dx.doi.org/10.1186/1744-8069-4-12] [PMID: 18416824]

Oshinsky, M.L.; Luo, J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache, 2006, 46(Suppl. 1), S39-S44.
[http://dx.doi.org/10.1111/j.1526-4610.2006.00489.x] [PMID: 16927963]

Lukács, M.; Warfvinge, K.; Tajti, J.; Fülöp, F.; Toldi, J.; Vécsei, L.; Edvinsson, L. Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72). J. Headache Pain, 2017, 18(1), 39.
[http://dx.doi.org/10.1186/s10194-017-0746-x] [PMID: 28337634]

Monaghan, D.T.; Bridges, R.J.; Cotman, C.W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol., 1989, 29, 365-402.
[http://dx.doi.org/10.1146/annurev.pa.29.040189.002053] [PMID: 2543272]

Traynelis, S.F.; Wollmuth, L.P.; McBain, C.J.; Menniti, F.S.; Vance, K.M.; Ogden, K.K.; Hansen, K.B.; Yuan, H.; Myers, S.J.; Dingledine, R. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev., 2010, 62(3), 405-496.
[http://dx.doi.org/10.1124/pr.109.002451] [PMID: 20716669]

Kumar, J.; Mayer, M.L. Functional insights from glutamate receptor ion channel structures. Annu. Rev. Physiol., 2013, 75, 313-337.
[http://dx.doi.org/10.1146/annurev-physiol-030212-183711] [PMID: 22974439]

Paoletti, P.; Neyton, J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol., 2007, 7(1), 39-47.
[http://dx.doi.org/10.1016/j.coph.2006.08.011] [PMID: 17088105]

Kaszaki, J.; Erces, D.; Varga, G.; Szabó, A.; Vécsei, L.; Boros, M. Kynurenines and intestinal neurotransmission: the role of N-methyl-D-aspartate receptors. J. Neural Transm. (Vienna), 2012, 119(2), 211-223.
[http://dx.doi.org/10.1007/s00702-011-0658-x] [PMID: 21617892]

Chan, K. MaassenVanDenBrink, A. Glutamate receptor antagonists in the management of migraine. Drugs, 2014, 74(11), 1165-1176.
[http://dx.doi.org/10.1007/s40265-014-0262-0] [PMID: 25030431]

Yin, S.; Niswender, C.M. Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications. Cell. Signal., 2014, 26(10), 2284-2297.
[http://dx.doi.org/10.1016/j.cellsig.2014.04.022] [PMID: 24793301]

Tsuchiya, D.; Kunishima, N.; Kamiya, N.; Jingami, H.; Morikawa, K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd³⁺. Proc. Natl. Acad. Sci. USA, 2002, 99(5), 2660-2665.
[http://dx.doi.org/10.1073/pnas.052708599] [PMID: 11867751]

Muto, T.; Tsuchiya, D.; Morikawa, K.; Jingami, H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc. Natl. Acad. Sci. USA, 2007, 104(10), 3759-3764.
[http://dx.doi.org/10.1073/pnas.0611577104] [PMID: 17360426]

Kaube, H.; Herzog, J.; Käufer, T.; Dichgans, M.; Diener, H.C. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology, 2000, 55(1), 139-141.
[http://dx.doi.org/10.1212/WNL.55.1.139] [PMID: 10891926]

Afridi, S.K.; Giffin, N.J.; Kaube, H.; Goadsby, P.J. A ran-domized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology, 2013, 80(7), 642-647.
[http://dx.doi.org/10.1212/WNL.0b013e3182824e66] [PMID: 23365053]

Weiss, B.; Alt, A.; Ogden, A.M.; Gates, M.; Dieckman, D.K.; Clemens-Smith, A.; Ho, K.H.; Jarvie, K.; Rizkalla, G.; Wright, R.A.; Calligaro, D.O.; Schoepp, D.; Mattiuz, E.L.; Stratford, R.E.; Johnson, B.; Salhoff, C.; Katofiasc, M.; Phebus, L.A.; Schenck, K.; Cohen, M.; Filla, S.A.; Ornstein, P.L.; Johnson, K.W.; Bleakman, D. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J. Pharmacol. Exp. Ther., 2006, 318(2), 772-781.
[http://dx.doi.org/10.1124/jpet.106.101428] [PMID: 16690725]

Sang, C.N.; Ramadan, N.M.; Wallihan, R.G.; Chappell, A.S.; Freitag, F.G.; Smith, T.R.; Silberstein, S.D.; Johnson, K.W.; Phebus, L.A.; Bleakman, D.; Ornstein, P.L.; Arnold, B.; Tepper, S.J.; Vandenhende, F. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia, 2004, 24(7), 596-602.
[http://dx.doi.org/10.1111/j.1468-2982.2004.00723.x] [PMID: 15196302]

Johnson, K.W.N.E.; Johnson, M.P.; Dieckman, D.K.; Clemens-Smith, A.; Siuda, E.R.; Dell, C.P.; Dehlinger, V.; Hudziak, K.J.; Filla, S.A.; Ornstein, P.L.; Ramadan, N.M.; Bleakman, D. Innovative drug development for headache disorders: glutamate.Innovative Drug Development for Headache Disorders; Olesen, J; Ramadan, N., Ed.; Oxford Univ. Press: Oxford, UK, 2008, pp. 185-194.
[http://dx.doi.org/10.1093/med/9780199552764.003.0022]

Goadsby, P.J.K.C. Investigation of the role of mGluR5 inhibition in migraine: a proof of concept study of ADX10059 in acute migraine treatment. Cephalalgia, 2009, 29(Suppl. 1), 7.

Edvinsson, L.; Ekman, R.; Jansen, I.; McCulloch, J.; Uddman, R. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J. Cereb. Blood Flow Metab., 1987, 7(6), 720-728.
[http://dx.doi.org/10.1038/jcbfm.1987.126] [PMID: 3500957]

Knyihar-Csillik, E.; Tajti, J.; Mohtasham, S.; Sari, G.; Vecsei, L. Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache. Neurosci. Lett., 1995, 184(3), 189-192.
[http://dx.doi.org/10.1016/0304-3940(94)11203-U] [PMID: 7715843]

Steenbergh, P.H.; Höppener, J.W.; Zandberg, J.; Visser, A.; Lips, C.J.; Jansz, H.S. Structure and expression of the human calcitonin/CGRP genes. FEBS Lett., 1986, 209(1), 97-103.
[http://dx.doi.org/10.1016/0014-5793(86)81091-2] [PMID: 3492393]

Lou, H.; Gagel, R.F. Alternative RNA processing--its role in regulating expression of calcitonin/calcitonin gene-related peptide. J. Endocrinol., 1998, 156(3), 401-405.
[http://dx.doi.org/10.1677/joe.0.1560401] [PMID: 9582495]

Mulderry, P.K.; Ghatei, M.A.; Bishop, A.E.; Allen, Y.S.; Polak, J.M.; Bloom, S.R. Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul. Pept., 1985, 12(2), 133-143.
[http://dx.doi.org/10.1016/0167-0115(85)90194-6] [PMID: 3877953]

Choksi, T.; Hay, D.L.; Legon, S.; Poyner, D.R.; Hagner, S.; Bloom, S.R.; Smith, D.M. Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines. Br. J. Pharmacol., 2002, 136(5), 784-792.
[http://dx.doi.org/10.1038/sj.bjp.0704761] [PMID: 12086988]

Walker, C.S.; Conner, A.C.; Poyner, D.R.; Hay, D.L. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol. Sci., 2010, 31(10), 476-483.
[http://dx.doi.org/10.1016/j.tips.2010.06.006] [PMID: 20633935]

Goadsby, P.J.; Edvinsson, L.; Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol., 1990, 28(2), 183-187.
[http://dx.doi.org/10.1002/ana.410280213] [PMID: 1699472]

Bellamy, J.L.; Cady, R.K.; Durham, P.L. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache, 2006, 46(1), 24-33.
[http://dx.doi.org/10.1111/j.1526-4610.2006.00294.x] [PMID: 16412148]

van Dongen, R.M.; Zielman, R.; Noga, M.; Dekkers, O.M.; Hankemeier, T.; van den Maagdenberg, A.M.; Terwindt, G.M.; Ferrari, M.D. Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis. Cephalalgia, 2017, 37(1), 49-63.
[http://dx.doi.org/10.1177/0333102415625614] [PMID: 26888294]

Eftekhari, S.; Salvatore, C.A.; Johansson, S.; Chen, T.B.; Zeng, Z.; Edvinsson, L. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res., 2015, 1600, 93-109.
[http://dx.doi.org/10.1016/j.brainres.2014.11.031] [PMID: 25463029]

Eftekhari, S.; Salvatore, C.A.; Gaspar, R.C.; Roberts, R.; O’Malley, S.; Zeng, Z.; Edvinsson, L. Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex. Cerebellum, 2013, 12(6), 937-949.
[http://dx.doi.org/10.1007/s12311-013-0509-4] [PMID: 23917876]

Csati, A.; Tajti, J.; Tuka, B.; Edvinsson, L.; Warfvinge, K. Calcitonin gene-related peptide and its receptor components in the human sphenopalatine ganglion -- interaction with the sensory system. Brain Res., 2012, 1435, 29-39.
[http://dx.doi.org/10.1016/j.brainres.2011.11.058] [PMID: 22208649]

Knyihár-Csillik, E.; Tajti, J.; Chadaide, Z.; Csillik, B.; Vécsei, L. Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model. Microsc. Res. Tech., 2001, 53(3), 193-211.
[http://dx.doi.org/10.1002/jemt.1084] [PMID: 11301495]

Lukács, M.; Haanes, K.A.; Majláth, Z.; Tajti, J.; Vécsei, L.; Warfvinge, K.; Edvinsson, L. Dural administration of inflammatory soup or Complete Freund’s Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion. J. Headache Pain, 2015, 16, 564.
[http://dx.doi.org/10.1186/s10194-015-0564-y] [PMID: 26329487]

Tajti, J.; Kuris, A.; Vécsei, L.; Xu, C.B.; Edvinsson, L. Organ culture of the trigeminal ganglion induces enhanced expression of calcitonin gene-related peptide via activation of extracellular signal-regulated protein kinase 1/2. Cephalalgia, 2011, 31(1), 95-105.
[http://dx.doi.org/10.1177/0333102410382796] [PMID: 20851839]

Hou, J.F.; Yu, L.C. Blockade effects of BIBN4096BS on CGRP-induced inhibition on whole-cell K⁺ currents in spinal dorsal horn neuron of rats. Neurosci. Lett., 2010, 469(1), 15-18.
[http://dx.doi.org/10.1016/j.neulet.2009.11.035] [PMID: 19925849]

Iovino, M.; Feifel, U.; Yong, C.L.; Wolters, J.M.; Wallenstein, G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia, 2004, 24(8), 645-656.
[http://dx.doi.org/10.1111/j.1468-2982.2004.00726.x] [PMID: 15265053]

Olesen, J.; Diener, H.C.; Husstedt, I.W.; Goadsby, P.J.; Hall, D.; Meier, U.; Pollentier, S.; Lesko, L.M. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med., 2004, 350(11), 1104-1110.
[http://dx.doi.org/10.1056/NEJMoa030505] [PMID: 15014183]

Vécsei, L.; Szok, D.; Csáti, A.; Tajti, J. CGRP antagonists and antibodies for the treatment of migraine. Expert Opin. Investig. Drugs, 2015, 24(1), 31-41.
[http://dx.doi.org/10.1517/13543784.2015.960921] [PMID: 25219387]

Edvinsson, L.; Chan, K.Y.; Eftekhari, S.; Nilsson, E.; de Vries, R.; Säveland, H.; Dirven, C.M.; Danser, A.H. MaassenVanDenBrink, A. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia, 2010, 30(10), 1233-1240.
[http://dx.doi.org/10.1177/0333102410362122] [PMID: 20855369]

Tepper, S.J.; Cleves, C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr. Opin. Investig. Drugs, 2009, 10(7), 711-720.
[PMID: 19579177]

Goadsby, P.J.; Holland, P.R.; Martins-Oliveira, M.; Hoffmann, J.; Schankin, C.; Akerman, S. Pathophysiology of migraine: a disorder of sensory processing. Physiol. Rev., 2017, 97(2), 553-622.
[http://dx.doi.org/10.1152/physrev.00034.2015] [PMID: 28179394]

Marcus, R.; Goadsby, P.J.; Dodick, D.; Stock, D.; Manos, G.; Fischer, T.Z. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia, 2014, 34(2), 114-125.
[http://dx.doi.org/10.1177/0333102413500727] [PMID: 23965396]

Diener, H.C.; Barbanti, P.; Dahlöf, C.; Reuter, U.; Habeck, J.; Podhorna, J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia, 2011, 31(5), 573-584.
[http://dx.doi.org/10.1177/0333102410388435] [PMID: 21172952]

Voss, T.; Lipton, R.B.; Dodick, D.W.; Dupre, N.; Ge, J.Y.; Bachman, R.; Assaid, C.; Aurora, S.K.; Michelson, D. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia, 2016, 36(9), 887-898.
[http://dx.doi.org/10.1177/0333102416653233] [PMID: 27269043]

Wrobel Goldberg, S.; Silberstein, S.D. Targeting CGRP: A new era for migraine treatment. CNS Drugs, 2015, 29(6), 443-452.
[http://dx.doi.org/10.1007/s40263-015-0253-z] [PMID: 26138383]

Pellesi, L.; Guerzoni, S.; Pini, L.A. Spotlight on Anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin. Pharmacol. Drug Dev., 2017, 6(6), 534-547.
[http://dx.doi.org/10.1002/cpdd.345] [PMID: 28409893]

Edvinsson, L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br. J. Clin. Pharmacol., 2015, 80(2), 193-199.
[http://dx.doi.org/10.1111/bcp.12618] [PMID: 25731075]

Azanza, J.R.; Sádaba, B.; Gómez-Guiu, A. Monoclonal antibodies: pharmacokinetics as a basis for new dosage regimens? J. Oncol. Pharm. Pract., 2015, 21(5), 370-376.
[http://dx.doi.org/10.1177/1078155214538085] [PMID: 24903270]

Bigal, M.E.; Walter, S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs, 2014, 28(5), 389-399.
[http://dx.doi.org/10.1007/s40263-014-0156-4] [PMID: 24638916]

Zhou, H.; Mascelli, M.A. Mechanisms of monoclonal antibody-drug interactions. Annu. Rev. Pharmacol. Toxicol., 2011, 51, 359-372.
[http://dx.doi.org/10.1146/annurev-pharmtox-010510-100510] [PMID: 20936946]

Descotes, J. Immunotoxicity of monoclonal antibodies. MAbs, 2009, 1(2), 104-111.
[http://dx.doi.org/10.4161/mabs.1.2.7909] [PMID: 20061816]

Vial, T.; Choquet-Kastylevsky, G.; Descotes, J. Adverse effects of immunotherapeutics involving the immune system. Toxicology, 2002, 174(1), 3-11.
[http://dx.doi.org/10.1016/S0300-483X(02)00051-3] [PMID: 11972986]

Stallmach, A.; Giese, T.; Schmidt, C.; Meuer, S.C.; Zeuzem, S.S. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur. J. Gastroenterol. Hepatol., 2004, 16(6), 627-630.
[http://dx.doi.org/10.1097/00042737-200406000-00018] [PMID: 15167167]

Dodick, D.W.; Goadsby, P.J.; Spierings, E.L.; Scherer, J.C.; Sweeney, S.P.; Grayzel, D.S. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol., 2014, 13(9), 885-892.
[http://dx.doi.org/10.1016/S1474-4422(14)70128-0] [PMID: 25127173]

Dodick, D.W.; Goadsby, P.J.; Spierings, E.L.; Scherer, J.C.; Sweeney, S.P.; Grayzel, D.S. Site of effect of LY2951742 for migraine prophylaxis--authors’ reply. Lancet Neurol., 2015, 14(1), 32-33.
[http://dx.doi.org/10.1016/S1474-4422(14)70309-6] [PMID: 25496895]

Sun, H.; Dodick, D.W.; Silberstein, S.; Goadsby, P.J.; Reuter, U.; Ashina, M.; Saper, J.; Cady, R.; Chon, Y.; Dietrich, J.; Lenz, R. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol., 2016, 15(4), 382-390.
[http://dx.doi.org/10.1016/S1474-4422(16)00019-3] [PMID: 26879279]

Bigal, M.E.; Dodick, D.W.; Rapoport, A.M.; Silberstein, S.D.; Ma, Y.; Yang, R.; Loupe, P.S.; Burstein, R.; Newman, L.C.; Lipton, R.B. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol., 2015, 14(11), 1081-1090.
[http://dx.doi.org/10.1016/S1474-4422(15)00249-5] [PMID: 26432182]

Bigal, M.E.; Edvinsson, L.; Rapoport, A.M.; Lipton, R.B.; Spierings, E.L.; Diener, H.C.; Burstein, R.; Loupe, P.S.; Ma, Y.; Yang, R.; Silberstein, S.D. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol., 2015, 14(11), 1091-1100.
[http://dx.doi.org/10.1016/S1474-4422(15)00245-8] [PMID: 26432181]

IHC oral abstracts and posters, Cephalalgia, 2017, 37(Issue 1_suppl)

Linde, M.; Gustavsson, A.; Stovner, L.J.; Steiner, T.J.; Barré, J.; Katsarava, Z.; Lainez, J.M.; Lampl, C.; Lantéri-Minet, M.; Rastenyte, D.; Ruiz de la Torre, E.; Tassorelli, C.; Andrée, C. The cost of headache disorders in Europe: the Eurolight project. Eur. J. Neurol., 2012, 19(5), 703-711.
[http://dx.doi.org/10.1111/j.1468-1331.2011.03612.x] [PMID: 22136117]

Miyata, A.; Arimura, A.; Dahl, R.R.; Minamino, N.; Uehara, A.; Jiang, L.; Culler, M.D.; Coy, D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun., 1989, 164(1), 567-574.
[http://dx.doi.org/10.1016/0006-291X(89)91757-9] [PMID: 2803320]

Emery, A.C.; Alvarez, R.A.; Abboud, P.; Xu, W.; Westover, C.D.; Eiden, M.V.; Eiden, L.E. C-terminal amidation of PACAP-38 and PACAP-27 is dispensable for biological activity at the PAC1 receptor. Peptides, 2016, 79, 39-48.
[http://dx.doi.org/10.1016/j.peptides.2016.03.003] [PMID: 26976270]

Banks, W.A.; Kastin, A.J.; Komaki, G.; Arimura, A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J. Pharmacol. Exp. Ther., 1993, 267(2), 690-696.
[PMID: 8246142]

Tajti, J.; Szok, D.; Nagy-Grocz, G.; Tuka, B.; Petrovics-Balog, A.; Toldi, J.; Vecsei, L. Kynurenines and PACAP in migraine: medicinal chemistry and pathogenetic aspects. Curr. Med. Chem., 2017, 24(13), 1332-1349.
[http://dx.doi.org/10.2174/0929867324666170227115019] [PMID: 28245765]

Vécsei, L.; Tuka, B.; Tajti, J. Role of PACAP in migraine headaches. Brain, 2014, 137(Pt 3), 650-651.
[http://dx.doi.org/10.1093/brain/awu014] [PMID: 24549810]

Tajti, J.; Uddman, R.; Edvinsson, L. Neuropeptide localization in the “migraine generator” region of the human brainstem. Cephalalgia, 2001, 21(2), 96-101.
[http://dx.doi.org/10.1046/j.1468-2982.2001.00140.x] [PMID: 11422090]

Tajti, J.; Uddman, R.; Möller, S.; Sundler, F.; Edvinsson, L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J. Auton. Nerv. Syst., 1999, 76(2-3), 176-183.
[http://dx.doi.org/10.1016/S0165-1838(99)00024-7] [PMID: 10412842]

Uddman, R.; Tajti, J.; Hou, M.; Sundler, F.; Edvinsson, L. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia, 2002, 22(2), 112-116.
[http://dx.doi.org/10.1046/j.1468-2982.2002.00324.x] [PMID: 11972578]

Uddman, R.; Tajti, J.; Möller, S.; Sundler, F.; Edvinsson, L. Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res., 1999, 826(2), 193-199.
[http://dx.doi.org/10.1016/S0006-8993(99)01260-3] [PMID: 10224296]

Steinberg, A.; Frederiksen, S.D.; Blixt, F.W.; Warfvinge, K.; Edvinsson, L. Expression of messenger molecules and receptors in rat and human sphenopalatine ganglion indicating therapeutic targets. J. Headache Pain, 2016, 17(1), 78.
[http://dx.doi.org/10.1186/s10194-016-0664-3] [PMID: 27587062]

Tuka, B.; Helyes, Z.; Markovics, A.; Bagoly, T.; Szolcsányi, J.; Szabó, N.; Tóth, E.; Kincses, Z.T.; Vécsei, L.; Tajti, J. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia, 2013, 33(13), 1085-1095.
[http://dx.doi.org/10.1177/0333102413483931] [PMID: 23598374]

Tuka, B.; Szabó, N.; Tóth, E.; Kincses, Z.T.; Párdutz, Á.; Szok, D.; Körtési, T.; Bagoly, T.; Helyes, Z.; Edvinsson, L.; Vécsei, L.; Tajti, J. Release of PACAP-38 in episodic cluster headache patients - an exploratory study. J. Headache Pain, 2016, 17(1), 69.
[http://dx.doi.org/10.1186/s10194-016-0660-7] [PMID: 27475101]

Amin, F.M.; Hougaard, A.; Magon, S.; Asghar, M.S.; Ahmad, N.N.; Rostrup, E.; Sprenger, T.; Ashina, M. Change in brain network connectivity during PACAP38-induced migraine attacks: A resting-state functional MRI study. Neurology, 2016, 86(2), 180-187.
[http://dx.doi.org/10.1212/WNL.0000000000002261] [PMID: 26674334]

Schytz, H.W.; Olesen, J.; Ashina, M. The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics, 2010, 7(2), 191-196.
[http://dx.doi.org/10.1016/j.nurt.2010.02.003] [PMID: 20430318]

Laburthe, M.; Couvineau, A.; Tan, V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides, 2007, 28(9), 1631-1639.
[http://dx.doi.org/10.1016/j.peptides.2007.04.026] [PMID: 17574305]

Schäfer, H.; Zheng, J.; Morys-Wortmann, C.; Fölsch, U.R.; Schmidt, W.E. Structural motifs of pituitary adenylate cyclase-activating polypeptide (PACAP) defining PAC1-receptor selectivity. Regul. Pept., 1999, 79(2-3), 83-92.
[http://dx.doi.org/10.1016/S0167-0115(98)00147-5] [PMID: 10100920]

Akerman, S.; Goadsby, P.J. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. Sci. Transl. Med., 2015, 7(308)308ra157
[http://dx.doi.org/10.1126/scitranslmed.aaa7557] [PMID: 26446954]

Davis-Taber, R.; Baker, S.; Lehto, S.G.; Zhong, C.; Surowy, C.S.; Faltynek, C.R.; Scott, V.E.; Honore, P. Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states. J. Pain, 2008, 9(5), 449-456.
[http://dx.doi.org/10.1016/j.jpain.2008.01.329] [PMID: 18337184]

Vollesen, A.L.; Guo, S.; Ashina, M. PACAP38 dose-response pilot study in migraine patients. Cephalalgia, 2017, 37(4), 391-395.
[http://dx.doi.org/10.1177/0333102416644435] [PMID: 27084887]

Vécsei, L.; Szalárdy, L.; Fülöp, F.; Toldi, J. Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov., 2013, 12(1), 64-82.
[http://dx.doi.org/10.1038/nrd3793] [PMID: 23237916]

Bohár, Z.; Toldi, J.; Fülöp, F.; Vécsei, L. Changing the face of kynurenines and neurotoxicity: therapeutic considerations. Int. J. Mol. Sci., 2015, 16(5), 9772-9793.
[http://dx.doi.org/10.3390/ijms16059772] [PMID: 25938971]

Hartai, Z.; Juhász, A.; Rimanóczy, A.; Janáky, T.; Donkó, T.; Dux, L.; Penke, B.; Tóth, G.K.; Janka, Z.; Kálmán, J. Decreased serum and red blood cell kynurenic acid levels in Alzheimer’s disease. Neurochem. Int., 2007, 50(2), 308-313.
[http://dx.doi.org/10.1016/j.neuint.2006.08.012] [PMID: 17023091]

Zádori, D.; Klivényi, P.; Toldi, J.; Fülöp, F.; Vécsei, L. Kynurenines in Parkinson’s disease: therapeutic perspectives. J. Neural Transm. (Vienna), 2012, 119(2), 275-283.
[http://dx.doi.org/10.1007/s00702-011-0697-3] [PMID: 21858430]

Szalardy, L.; Klivenyi, P.; Zadori, D.; Fulop, F.; Toldi, J.; Vecsei, L. Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Curr. Med. Chem., 2012, 19(13), 1899-1920.
[http://dx.doi.org/10.2174/092986712800167365] [PMID: 22429096]

Rejdak, K.; Bartosik-Psujek, H.; Dobosz, B.; Kocki, T.; Grieb, P.; Giovannoni, G.; Turski, W.A.; Stelmasiak, Z. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci. Lett., 2002, 331(1), 63-65.
[http://dx.doi.org/10.1016/S0304-3940(02)00710-3] [PMID: 12359324]

Fejes, A.; Párdutz, A.; Toldi, J.; Vécsei, L. Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives. Curr. Neuropharmacol., 2011, 9(2), 376-387.
[http://dx.doi.org/10.2174/157015911795596621] [PMID: 22131946]

Prescott, C.; Weeks, A.M.; Staley, K.J.; Partin, K.M. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett., 2006, 402(1-2), 108-112.
[http://dx.doi.org/10.1016/j.neulet.2006.03.051] [PMID: 16644124]

Rózsa, E.; Robotka, H.; Vécsei, L.; Toldi, J. The Janus-face kynurenic acid. J. Neural Transm. (Vienna), 2008, 115(8), 1087-1091.
[http://dx.doi.org/10.1007/s00702-008-0052-5] [PMID: 18446262]

Vécsei, L.; Miller, J.; MacGarvey, U.; Beal, M.F. Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res. Bull., 1992, 28(2), 233-238.
[http://dx.doi.org/10.1016/0361-9230(92)90184-Y] [PMID: 1596743]

Vámos, E.; Párdutz, A.; Varga, H.; Bohár, Z.; Tajti, J.; Fülöp, F.; Toldi, J.; Vécsei, L. l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology, 2009, 57(4), 425-429.
[http://dx.doi.org/10.1016/j.neuropharm.2009.06.033] [PMID: 19580819]

Knyihár-Csillik, E.; Toldi, J.; Mihály, A.; Krisztin-Péva, B.; Chadaide, Z.; Németh, H.; Fenyo, R.; Vécsei, L. Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J. Neural Transm. (Vienna), 2007, 114(4), 417-421.
[http://dx.doi.org/10.1007/s00702-006-0545-z] [PMID: 16897600]

Röver, S.; Cesura, A.M.; Huguenin, P.; Kettler, R.; Szente, A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem., 1997, 40(26), 4378-4385.
[http://dx.doi.org/10.1021/jm970467t] [PMID: 9435907]

Walsh, H.A.; Leslie, P.L.; O’Shea, K.C.; Botting, N.P. 2-Amino-4-[3′-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg. Med. Chem. Lett., 2002, 12(3), 361-363.
[http://dx.doi.org/10.1016/S0960-894X(01)00758-2] [PMID: 11814797]

Gellért, L.; Fuzik, J.; Göblös, A.; Sárközi, K.; Marosi, M.; Kis, Z.; Farkas, T.; Szatmári, I.; Fülöp, F.; Vécsei, L.; Toldi, J. Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur. J. Pharmacol., 2011, 667(1-3), 182-187.
[http://dx.doi.org/10.1016/j.ejphar.2011.05.069] [PMID: 21664350]

Zádori, D.; Nyiri, G.; Szonyi, A.; Szatmári, I.; Fülöp, F.; Toldi, J.; Freund, T.F.; Vécsei, L.; Klivényi, P. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease. J. Neural Transm. (Vienna), 2011, 118(6), 865-875.
[http://dx.doi.org/10.1007/s00702-010-0573-6] [PMID: 21194001]

Demeter, I.; Nagy, K.; Gellért, L.; Vécsei, L.; Fülöp, F.; Toldi, J. A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study: special issue related to kynurenine. J. Neural Transm. (Vienna), 2012, 119(2), 151-154.
[http://dx.doi.org/10.1007/s00702-011-0755-x] [PMID: 22231843]

Lukács, M.; Warfvinge, K.; Kruse, L.S.; Tajti, J.; Fülöp, F.; Toldi, J.; Vécsei, L.; Edvinsson, L. KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion. J. Headache Pain, 2016, 17(1), 64.
[http://dx.doi.org/10.1186/s10194-016-0654-5] [PMID: 27377707]

Csáti, A.; Edvinsson, L.; Vécsei, L.; Toldi, J.; Fülöp, F.; Tajti, J.; Warfvinge, K. Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion. J. Headache Pain, 2015, 16, 99.
[http://dx.doi.org/10.1186/s10194-015-0581-x] [PMID: 26627709]

Fülöp, F.; Szatmári, I.; Vámos, E.; Zádori, D.; Toldi, J.; Vécsei, L. Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr. Med. Chem., 2009, 16(36), 4828-4842.
[http://dx.doi.org/10.2174/092986709789909602] [PMID: 19929784]

Fülöp, F.; Szatmári, I.; Toldi, J.; Vécsei, L. Modifications on the carboxylic function of kynurenic acid. J. Neural Transm. (Vienna), 2012, 119(2), 109-114.
[http://dx.doi.org/10.1007/s00702-011-0721-7] [PMID: 21997444]

Veres, G.; Fejes-Szabó, A.; Zádori, D.; Nagy-Grócz, G.; László, A.M.; Bajtai, A.; Mándity, I.; Szentirmai, M.; Bohár, Z.; Laborc, K.; Szatmári, I.; Fülöp, F.; Vécsei, L.; Párdutz, Á. A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study. J. Neural Transm. (Vienna), 2017, 124(1), 99-112.
[http://dx.doi.org/10.1007/s00702-016-1615-5] [PMID: 27629500]

Zádori, D.; Ilisz, I.; Klivényi, P.; Szatmári, I.; Fülöp, F.; Toldi, J.; Vécsei, L.; Péter, A. Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. J. Pharm. Biomed. Anal., 2011, 55(3), 540-543.
[http://dx.doi.org/10.1016/j.jpba.2011.02.014] [PMID: 21392919]

Fejes-Szabó, A.; Bohár, Z.; Vámos, E.; Nagy-Grócz, G.; Tar, L.; Veres, G.; Zádori, D.; Szentirmai, M.; Tajti, J.; Szatmári, I.; Fülöp, F.; Toldi, J.; Párdutz, Á.; Vécsei, L. Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex. J. Neural Transm. (Vienna), 2014, 121(7), 725-738.
[http://dx.doi.org/10.1007/s00702-013-1146-2] [PMID: 24385076]

Lukacs, M.; Tajti, J.; Fulop, F.; Toldi, J.; Edvinsson, L.; Vecsei, L. Migraine, neurogenic inflammation, drug development - pharmacochemical aspects. Curr. Med. Chem., 2017, 24(33), 3649-3665.
[http://dx.doi.org/10.2174/0929867324666170712163437] [PMID: 28707585]

Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature, 1997, 389(6653), 816-824.
[http://dx.doi.org/10.1038/39807] [PMID: 9349813]

Ji, R.R.; Samad, T.A.; Jin, S.X.; Schmoll, R.; Woolf, C.J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron, 2002, 36(1), 57-68.
[http://dx.doi.org/10.1016/S0896-6273(02)00908-X] [PMID: 12367506]

Kitagawa, Y.; Tamai, I.; Hamada, Y.; Usui, K.; Wada, M.; Sakata, M.; Matsushita, M. Orally administered selective TRPV1 antagonist, JTS-653, attenuates chronic pain refractory to non-steroidal anti-inflammatory drugs in rats and mice including post-herpetic pain. J. Pharmacol. Sci., 2013, 122(2), 128-137.
[http://dx.doi.org/10.1254/jphs.12276FP] [PMID: 23728381]

Summ, O.; Holland, P.R.; Akerman, S.; Goadsby, P.J. TRPV1 receptor blockade is ineffective in different in vivo models of migraine. Cephalalgia, 2011, 31(2), 172-180.
[http://dx.doi.org/10.1177/0333102410375626] [PMID: 20974587]

Lambert, G.A.; Davis, J.B.; Appleby, J.M.; Chizh, B.A.; Hoskin, K.L.; Zagami, A.S. The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission. Naunyn Schmiedebergs Arch. Pharmacol., 2009, 380(4), 311-325.
[http://dx.doi.org/10.1007/s00210-009-0437-5] [PMID: 19690836]

Gunthorpe, M.J.; Hannan, S.L.; Smart, D.; Jerman, J.C.; Arpino, S.; Smith, G.D.; Brough, S.; Wright, J.; Egerton, J.; Lappin, S.C.; Holland, V.A.; Winborn, K.; Thompson, M.; Rami, H.K.; Randall, A.; Davis, J.B. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J. Pharmacol. Exp. Ther., 2007, 321(3), 1183-1192.
[http://dx.doi.org/10.1124/jpet.106.116657] [PMID: 17392405]

Chizh, B.P.J.; Lai, R.; Guillard, F.; Bullman, J.; Baines, A.; Napolitano, A.; Appleby, J. A randomised, two-period cross-over study to investigate the efficacy of the Trpv1 antagonist SB-705498 in acute migraine. Eur. J. Pain, 2009, 13, S202a-S202.
[http://dx.doi.org/10.1016/S1090-3801(09)60705-9]

Sicuteri, F.; Renzi, D.; Geppetti, P. Substance P and enkephalins: a creditable tandem in the pathophysiology of cluster headache and migraine. Adv Exp Med Biol, 1986, 198(Pt B), 145-152.
[http://dx.doi.org/10.1007/978-1-4757-0154-8_18] [PMID: 2433912]

Lee, W.S.; Moussaoui, S.M.; Moskowitz, M.A. Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br. J. Pharmacol., 1994, 112(3), 920-924.
[http://dx.doi.org/10.1111/j.1476-5381.1994.tb13168.x] [PMID: 7921621]

Diener, H.C.; Group, R.P.R.S. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia, 2003, 23(3), 183-185.
[http://dx.doi.org/10.1046/j.1468-2982.2003.00496.x] [PMID: 12662184]

Goldstein, D.J.; Offen, W.W.; Klein, E.G.; Phebus, L.A.; Hipskind, P.; Johnson, K.W.; Ryan, R.E. Jr. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia, 2001, 21(2), 102-106.
[http://dx.doi.org/10.1046/j.1468-2982.2001.00161.x] [PMID: 11422091]

Taffi, R.; Vignini, A.; Lanciotti, C.; Luconi, R.; Nanetti, L.; Mazzanti, L.; Provinciali, L.; Silvestrini, M.; Bartolini, M. Platelet membrane fluidity and peroxynitrite levels in migraine patients during headache-free periods. Cephalalgia, 2005, 25(5), 353-358.
[http://dx.doi.org/10.1111/j.1468-2982.2004.00863.x] [PMID: 15839850]

Lassen, L.H.; Christiansen, I.; Iversen, H.K.; Jansen-Olesen, I.; Olesen, J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia, 2003, 23(9), 877-886.
[http://dx.doi.org/10.1046/j.1468-2982.2003.00586.x] [PMID: 14616929]

Alderton, W.K.; Angell, A.D.; Craig, C.; Dawson, J.; Garvey, E.; Moncada, S.; Monkhouse, J.; Rees, D.; Russell, L.J.; Russell, R.J.; Schwartz, S.; Waslidge, N.; Knowles, R.G. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol., 2005, 145(3), 301-312.
[http://dx.doi.org/10.1038/sj.bjp.0706168] [PMID: 15778742]

Van der Schueren, B.J.; Lunnon, M.W.; Laurijssens, B.E.; Guillard, F.; Palmer, J.; Van Hecken, A.; Depré, M.; Vanmolkot, F.H.; de Hoon, J.N. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J. Clin. Pharmacol., 2009, 49(3), 281-290.
[http://dx.doi.org/10.1177/0091270008329548] [PMID: 19246728]

de Lecea, L.; Kilduff, T.S.; Peyron, C.; Gao, X.; Foye, P.E.; Danielson, P.E.; Fukuhara, C.; Battenberg, E.L.; Gautvik, V.T.; Bartlett, F.S., II; Frankel, W.N.; van den Pol, A.N.; Bloom, F.E.; Gautvik, K.M.; Sutcliffe, J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA, 1998, 95(1), 322-327.
[http://dx.doi.org/10.1073/pnas.95.1.322] [PMID: 9419374]

Sakurai, T.; Mieda, M.; Tsujino, N. The orexin system: roles in sleep/wake regulation. Ann. N. Y. Acad. Sci., 2010, 1200, 149-161.
[http://dx.doi.org/10.1111/j.1749-6632.2010.05513.x] [PMID: 20633143]

Holland, P.R.; Akerman, S.; Goadsby, P.J. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur. J. Neurosci., 2006, 24(10), 2825-2833.
[http://dx.doi.org/10.1111/j.1460-9568.2006.05168.x] [PMID: 17156207]

Chabi, A.; Zhang, Y.; Jackson, S.; Cady, R.; Lines, C.; Herring, W.J.; Connor, K.M.; Michelson, D. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia, 2015, 35(5), 379-388.
[http://dx.doi.org/10.1177/0333102414544979] [PMID: 25106663]